Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash from Investing Activities (2017 - 2025)

Historic Cash from Investing Activities for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $79.0 million.

  • Arcus Biosciences' Cash from Investing Activities rose 37241.38% to $79.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $299.0 million, marking a year-over-year increase of 37943.93%. This contributed to the annual value of -$84.0 million for FY2024, which is 14329.9% down from last year.
  • As of Q3 2025, Arcus Biosciences' Cash from Investing Activities stood at $79.0 million, which was up 37241.38% from $137.0 million recorded in Q2 2025.
  • Over the past 5 years, Arcus Biosciences' Cash from Investing Activities peaked at $137.0 million during Q2 2025, and registered a low of -$268.0 million during Q1 2022.
  • In the last 5 years, Arcus Biosciences' Cash from Investing Activities had a median value of $26.0 million in 2023 and averaged -$3.1 million.
  • As far as peak fluctuations go, Arcus Biosciences' Cash from Investing Activities soared by 1371029.41% in 2021, and later crashed by 725950.72% in 2022.
  • Arcus Biosciences' Cash from Investing Activities (Quarter) stood at $18.8 million in 2021, then soared by 150.24% to $47.0 million in 2022, then tumbled by 40.43% to $28.0 million in 2023, then soared by 82.14% to $51.0 million in 2024, then skyrocketed by 54.9% to $79.0 million in 2025.
  • Its Cash from Investing Activities was $79.0 million in Q3 2025, compared to $137.0 million in Q2 2025 and $32.0 million in Q1 2025.